The therapeutic potential of semi-synthetic artemisinin and synthetic endoperoxide antimalarial agents

Expert Opinion on Investigational Drugs

Volumn 14, Issue 9, 2005, Pages 1117-1128

  O'Neill, Paul M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Arteflene; Artemisinin; Artemisinin combination chemotherapy; Chemotherapy; Drug resistance; Malaria; OZ 227; Semi synthetic

Indexed keywords

1,2,4 TRIOXANE DERIVATIVE; AMANTADINE DERIVATIVE; AMODIAQUINE; ANTIMALARIAL AGENT; ARTEETHER; ARTEFLENE; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISIN DERIVATIVE; ARTEMISININ; ARTESUNATE; ARTESUNATE PLUS CHLORPROGUANIL PLUS DAPSONE; BO 7; CHLOROQUINE; DIHYDROARTEMISININ; ENDOPEROXIDE; FANSIDAR; FANSIMEF; FENOZAN; IRON; OZ 277; PIPERAQUINE; PYRONARIDINE; TETRAOXANE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG COST; DRUG HALF LIFE; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; FIRST PASS EFFECT; HUMAN; MALARIA FALCIPARUM; NEUROTOXICITY; NONHUMAN; PLASMODIUM FALCIPARUM; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SCALE UP; STRUCTURE ANALYSIS;

ANIMALS; ANTIMALARIALS; ARTEMISININS; HUMANS; MALARIA; PEROXIDES; SESQUITERPENES;

EID: 24344443742     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.9.1117     Document Type: Review

References (101)

1. BUTLER AR, WU YL: Artemisinin (qinghaosu) - a new type of antimalarial drug. Chem. Soc. Rev. (1992) 21(2):85-90.
2. KLAYMAN DL: Qinghaosu (artemisinin) - an antimalarial drug from China. Science (1985) 228(4703):1049-1055.
3. CASTEEL DA, PERI SP, GERENA L: Synthesis and antimalarial evaluation of 2,3,5-trioxabicyclo 2.2.3 nonane, a model for the putative pharmacophore of artemisinin. Bioorg. Med. Chem. Lett. (1993) 3(8):1707-1710.
4. WANG DR, LIN XY, ZHANG HZ: Thin-layer chromatographic fluorometry of artemisinin and deoxyartemisinin. Acta Pharmacologica Sinica (1987) 8(4):355-358.
5. LIN AJ, LI LQ, KLAYMAN DL, GEORGE CF, FLIPPEN ANDERSON JL: Antimalarial activity of new water-soluble dihydroartemisinin derivatives.3. Aromatic amine analogs. J. Med. Chem. (1990) 33(9):2610-2614.
6. LIN AJ, LI LQ, ANDERSEN SL, KLAYMAN DL: Antimalarial activity of new dihydroartemisinin derivatives.5. Sugar analogs. J. Med Chem. (1992) 35(9):1639-1642.
7. LIN AJ, LEE M, KLAYMAN DL: Antimalarial activity of new water-soluble dihydroartemisinin derivatives.2. Stereospecificity of the ether side-chain. J. Med. Chem. (1989) 32(6):1249-1252.
8. HAYNES RK, CHAN HW, CHEUNG MK et al.: C-10 ester and ether derivatives of dihydroartemisinin-10-α artesunate, preparation of authentic 10-β artesunate, and of other ester and ether derivatives bearing potential aromatic intercalating groups at C-10. Eur. J. Org. Chem. (2002) 1:113-132.
9. PHAN VT: Artemisinin and artesunate. Bulletin De La Societe De Pathologie Exotique (2002) 95(2):86-88.
10. BARRADELL LB, FITTON A: Artesunate - a review of its pharmacology and therapeutic efficacy in the treatment of malaria. Drugs (1995) 50(4):714-741.
11. SNOW RW, ECKERT E, TEKLEHAIMANOT A: Estimating the needs for artesunate-based combination therapy for malaria case-management in Africa. Trends Parasitol. (2003) 19(8):363-369.
12. YEUNG S, PONGTAVORNPINYO W, HASTINGS IM, MILLS AJ, WHITE NJ: Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Am. J. Trop. Med. Hyg. (2004) 71(2):179-186.
13. NOSTEN F, BRASSEUR P: Combination therapy for malaria - the way forward? Drugs (2002) 62(9):1315-1329.
14. WARHURST DC: Haemozoin and the mode of action of blood schizontocides - more controversy. Parasitol. Today (1995) 11(6):204-205.
15. GOLDBERG DE, SLATER AFG, BEAVIS R et al.: Hemoglobin degradation in the human malaria pathogen Plasmodium-falciparum - a catabolic pathway initiated by a specific aspartic protease. J. Exp. Med. (1991) 173(4):961-969.
16. MESHNICK SR, THOMAS A, RANZ A, XU CM, PAN HZ: Artemisinin (Qinghaosu) - the role of intracellular hemin in its mechanism of antimalarial action. Mol. Biochem. Parasitol. (1991) 49(2):181-190.
17. O'NEILL PM, POSNER GH: A medicinal chemistry perspective on artemisinin and related endoperoxides. J. Med. Chem. (2004) 47(12):2945-2964.
18. HONG YL, YANG YZ, MESHNICK SR: The interaction of artemisinin with malarial hemozoin. Mol. Biochem. Parasitol. (1994) 63(1):121-128.
19. ASAWAMAHASAKDA W, ITTARAT I, PU YM, ZIFFER H, MESHNICK SR: Reaction of antimalarial endoperoxides with specific parasite proteins. Antimicrob. Agents Chemother. (1994) 38(8):1854-1858.
20. PANDEY AV, BABBARWAL VK, OKOYEH JN et al.: Hemozoin formation in malaria: a two-step process involving histidine-rich proteins and lipids. Biochem. Biophys. Res. Commun. (2003) 308(4):736-743.
21. POSNER GH, OH CH: A Regiospecifically O-18 labeled 1,2,4-trioxane - a simple chemical-model system to probe the mechanism(s) for the antimalarial activity of artemisinin (qinghaosu). J. Am. Chem. Soc. (1992) 114(21):8328-8329.
22. JEFFORD CW, VICENTE MGH, JACQUIER Y et al.: The deoxygenation and isomerization of artemisinin and artemether and their relevance to antimalarial action. Helvetica Chimica Acta (1996) 79(5):1475-1487.
23. POSNER GH, WANG D, CUMMING JN et al.: Further evidence supporting the importance of and the restrictions on a carbon-centred radical for high antimalarial activity of 1,2,4-trioxanes like artemisinin. J. Med. Chem. (1995) 38(13):2273-2275.
24. OLLIARO PL, HAYNES RK, MEUNIER B, YUTHAVONG Y. Possible modes of action of the artemisinin-type compounds. Trends Parasitol. (2001) 17(3):122-126.
25. POSNER GH, MESHNICK SR: Radical mechanism of action of the artemisinin-type compounds. Trends Parasitol. (2001) 17(6):266-267.
26. OLLIARO PL, HAYNES RK, MEUNIER RK, MEUNIER B, YUTHAVONG Y: Radical mechanism of action of the artemisinin-type compounds - response. Trends Parasitol. (2001) 17(6):267-268.
27. HAYNES RK, PAI HHO, VOERSTE A: Ring opening of artemisinin (qinghaosu) and dihydroartemisinin and interception of the open hydroperoxides with formation of N-oxides - a chemical model for antimalarial mode of action. Tet. Letts (1999) 40(25):4715-4718.
28. WU YK, YUE ZY, WU YL: Interaction of qinghaosu (artemisinin) with cysteine sulfhydryl mediated by traces of non-heme iron. Angew. Chem. Int. Ed. (1999) 38(17):2580-2582.
29. WU YK, YUE ZY, LIU HH: New insights into the degradation or qinghaosu (artemisinin) mediated by non-heme-iron chelates, and their relevance to the antimalarial mechanism. Helvetica Chimica Acta (2001) 84(4):928-932.
30. WU YK: How might qinghaosu (artemisinin) and related compounds kill the intraerythrocytic malaria parasite? A chemists view. Acc. Chem. Res. (2002) 35(5):255-259.
31. BERMAN PA, ADAMS PA: Artemisinin enhances heme-catalysed oxidation of lipid membranes. Free Radic. Biol. Med. (1997) 22(7):1283-1288.
32. ZHANG F, GOSSER DK, MESHNICK SR: Hemin-catalyzed decomposition of artemisinin (qinghaosu). Biochem. Pharmacol. (1992) 43(8):1805-1809.
33. ROBERT A, MEUNIER B: Characterization of the first covalent adduct between artemisinin and a heme model. J. Am. Chem. Soc. (1997) 119(25):5968-5969.
34. ROBERT A, CAZELLES J, MEUNIER B: Characterization of the alkylation product of heme by the antimalarial drug artemisinin. Angew. Chem. Int. Ed. (2001) 40(10):1954-1957.
35. DUA M, TAKAKUWA Y, CHISHTI AH, HANSPAL M: Plasmodium falciparum derived cysteine protease falcipain-2 cleaves erythrocyte protein 4.1 within the spectrin-actin binding domain. Blood (2001) 98(11):25.
36. ECKSTEIN-LUDWIG U, WEBB RJ, VAN GOETHEM IDA et al..: Artemisinins target the SERCA of Plasmodium falciparum. Nature (2003) 424(6951):957-961.
37. HAYNES RK, KRISHNA S: Artemisinins: activities and actions. Microbes Infect. (2004) 6(14):1339-1346.
38. 2+-ATPase(PfATP6) and docking of artemisinin derivatives to PfATP6. Bioorg. Med. Chem. Lett. (2005) 15(12):2994-2997.
39. ROBERT A, DECHY-CABARET O, CAZELLES J, MEUNIER B: From mechanistic studies on artemisinin derivatives to new modular antimalarial drugs. Acc. Chem. Res. (2002) 35(3):167-174.
40. KRISHNA S, UHLEMANN AC, HAYNES RK: Artemisinins: mechanisms of action and potential for resistance. Drug Resist. Update (2004) 7(4-5):233-244.
41. O'NEILL PM, SCHEINMANN F, STACHULSKI AV, MAGGS JL, PARK BK: Efficient preparations of the β-glucuronides of dihydroartemisinin and structural confirmation of the human glucuronide metabolite. J. Med Chem. (2001) 44(9):1467-1470.
42. ILETT KF, ETHELL BT, MAGGS JL et al.: Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab. Dispos. (2002) 30(9):1005-1012.
43. GRACE JM, AGUILAR AJ, TROTMAN KM, BREWER TG: Metabolism of β-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450. Drug Metab. Dispos. (1998) 26(4):313-317.
44. POSNER GH, O'NEILL PM: Knowledge of the proposed chemical mechanism of action and cytochrome P450 metabolism of antimalarial trioxanes like artemisinin allows rational design of new antimalarial. Acc. Chem. Res. (2004) 37(6):397-404.
45. BATTY KT, ILETT KF, POWELL SM, MARTIN J, DAVIS TME: Relative bioavailability of artesunate and dihydroartemisinin: investigations in the isolated perfused rat liver and in healthy Caucasian volunteers. Am. J. Trop. Med. Hyg. (2002) 66(2):130-136.
46. WHO: Antimalarial drug combination therapy: report of a WHO technical consultation. Geneva: World Health Organization (2001):WHO/CDS/RBM/2001.2035.
47. WHITE NJ, OLLIARO PL: Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria. Parasitol. Today (1996) 12(10):399-401.
48. VAN DEN BROEK I, AMSALU R, BALASEGARAM M et al.: Efficacy of two artemisinin combination therapies for uncomplicated falciparum malaria in children under 5 years, Malakal, Upper Nile, Sudan. Malaria J. (2005) 4:14.
49. NARASIMHAN V, ATTARAN A: Roll back malaria? The scarcity of international aid for malaria control. Malaria J. (2003) 2:8.
50. HAYNES RK: Artemisinin and derivatives: the future for malaria treatment? Curr. Opin. Infect. Dis. (2001) 14(6):719-726.
51. BREWER TG, PEGGINS JO, GRATE SJ et al.: Neurotoxicity in animals due to arteether and artemether. Trans. R. Soc. Trop. Med. Hyg. (1994) 88:33-36.
52. HAYNES RK, VONWILLER SC: From qinghao, marvelous herb of antiquity, to the antimalarial trioxane qinghaosu - and some remarkable new chemistry. Acc. Chem. Res. (1997) 30(2):73-79.
53. O'DOWD H, PLOYPRADITH P, XIE SJ, SHAPIRO TA, POSNER GH: Antimalarial artemisinin analogs. Synthesis via chemoselective C-C bond formation and preliminary biological evaluation. Tetrahedron (1999) 55(12):3625-3636.
54. POSNER GH, PARKER MH, NORTHROP J et al.: Orally active, hydrolytically stable, semisynthetic, antimalarial trioxanes in the artemisinin Family. J. Med. Chem. (1999) 42(2):300-304.
55. POSNER GH, PAIK IH, SUR S et al.: Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high stability and efficacy. J. Med. Chem. (2003) 46(6):1060-1065.
56. AVERY MA, MURALEEDHARAN KM, DESAI PV et al.: Structure-activity relationships of the antimalarial agent artemisinin. 8. Design, synthesis, and CoMFA studies toward the development of artemisinin-based drugs against leishmaniasis and malaria. J. Med. Chem. (2003) 46(20):4244-4258.
57. VROMAN JA, ALVIM-GASTON M, AVERY MA: Current progress in the chemistry, medicinal chemistry and drug design of artemisinin based antimalarials. Curr. Pharm. Design (1999) 5(2):101-138.
58. JUNG M, ELSOHLY HN, McCHESNEY JD: A concise synthesis of novel C-13 functionalized deoxoartemisinins. Synlett (1993) 1:43-44.
59. HINDLEY S, WARD SA, STORR RC et al.: Mechanism-based design of parasite-targeted artemisinin derivatives: synthesis and antimalarial activity of new diamine containing analogues. J. Med. Chem. (2002) 45:1052-1063.
60. AVERY MA, ALVIM-GASTON M, VROMAN JA et al.: Structure-activity relationships of the antimalarial agent artemisinin. 7. Direct modification of (+)-artemisinin and in vivo antimalarial screening of new, potential preclinical antimalarial candidates. J. Med. Chem. (2002) 45(19):4321-4335.
61. HAYNES RK, HO WY, CHAN HW et al.: Highly antimalaria-active artemisinin derivatives: biological activity does not correlate with chemical reactivity. Angew. Chem. Int. Ed. (2004) 43(11):1381-1385.
62. AVERY MA, CHONG WKM, JENNINGSWHITE C: Stereoselective total synthesis of (+)-artemisinin, the antimalarial constituent of artemisia-annua L. J. Am. Chem. Soc. (1992) 114(3):974-979.
63. AVERY MA, ALVIM-GASTON M, RODRIGUES CR et al.: Structure-activity relationships of the antimalarial agent artemisinin. 6. The development of predictive in vitro potency models using CoMFA and HQSAR methodologies. J. Med. Chem. (2002) 45(2):292-303.
64. TANG YQ, DONG YX, VENNERSTROM JL: Synthetic peroxides as antimalarials. Med. Res. Rev. (2004) 24(4):425-448.
65. AVERY MA, JENNINGSWHITE C, CHONG WKM: The total synthesis of (+)-artemisinin and (+)-9-desmethylartemisinin. Tet. Letts (1987) 28(40):4629-4632.
66. PETERS W, ROBINSON BL, ROSSIER JC, MISRA D, JEFFORD CW: The chemotherapy of rodent malaria. 49. The activities of some synthetic 1,2,4-trioxanes against chloroquine-sensitive and chloroquine-resistant parasites.2. Structure-activity studies on cis-fused cyclopenteno-1,2,4-trioxanes (Fenozans) against drug-sensitive and drug-resistant lines of Plasmodium-Berghei and P-Yoelii spp Ns in vivo. Ann. Trop. Med. Parasitol. (1993) 87(2):221-221.
67. VENNERSTROM JL, DONG YX, ANDERSEN SL et al..: Synthesis and antimalarial activity of sixteen dispiro-1,2,4,5- tetraoxanes: alkyl-substituted 7,8,15,16- tetraoxadispiro 5.2.5.2 hexadecanes. J. Med. Chem. (2000) 43(14):2753-2758.
68. VENNERSTROM JL, AGER AL, ANDERSEN SL et al.: Assessment of the antimalarial potential of tetraoxane WR 148999. Am. J. Trop. Med. Hyg. (2000) 62(5):573-578.
69. McCULLOUGH KJ, WOOD JK, BHATTACHARJEE AK et al.: Methyl-substituted dispiro- 1,2,4,5-tetroxanes: correlations of structural studies with antimalarial activity. J. Med. Chem. (2000) 43:1246-1249.
70. HOFHEINZ W, BURGIN H, GOCKE E et al.: Ro-42-1611 (arteflene), a new effective antimalarial - chemical-structure and biological-activity. Trop. Med. Parasitol. (1994) 45(3):261-265.
71. BACHI MD, KORSHIN EE, HOOS R et al..: A short synthesis and biological evaluation of potent and nontoxic antimalarial bridged bicyclic β-sulfonyl-endoperoxides. J. Med. Chem. (2003) 46(12):2516-2533.
72. KIM HS, NAGAI Y, ONO K et al.: Synthesis and antimalarial activity of novel medium-sized 1,2,4,5-tetraoxacycloalkanes. J. Med. Chem. (2001) 44(14):2357-2361.
73. POSNER GH, CUMMING JN, WOO SH et al.: Orally active antimalarial 3-substituted trioxanes: new synthetic methodology and biological evaluation. J. Med. Chem. (1998) 41(6):940-951.
74. POSNER GH, JEON HB, PLOYPRADITH P et al.: Orally active, water-soluble antimalarial 3-aryltrioxanes: short synthesis and preclinical efficacy testing in rodents. J. Med. Chem. (2002) 45(18):3824-3828.
75. SINGH C, MISRA D, SAXENA G, CHANDRA S: Synthesis of in vivo potent antimalarial 1,2,4-trioxanes. Bioorg. Med. Chem. Lett. (1992) 2(5):497-500.
76. SINGH C, GUPTA N, PURI SK: Photo-oxygenation of geraniol: synthesis of a novel series of hydroxy-functionalized antimalarial 1,2,4-trioxanes. Bioorg. Med. Chem. Lett. (2002) 12(15):1913-1916.
77. O'NEILL PM, PUGH M, DAVIES J, WARD SA, PARK BK: Regioselective Mukaiyama hydroperoxysilylation of 2-alkyl- or 2-aryl-prop-2-en-1-ols: application to a new synthesis of 1,2,4-trioxanes. Tet. Letts (2001) 42(27):4569-4571.
78. O'NEILL PM, HINDLEY S, PUGH MD et al.: Co(thd)(2): a superior catalyst for aerobic epoxidation and hydroperoxysilylation of unactivated alkenes: application to the synthesis of spiro-1,2,4-trioxanes. Tet. Letts (2003) 44(44):8135-8138.
79. VENNERSTROM JL, ARBE-BARNES S, BRUN R et al.: Identification of an antimalarial synthetic trioxolane drug development candidate. Nature (2004) 430(7002):900-904.
80. TANG YQ, DONG YX, KARLE JM, DITUSA CA, VENNERSTROM JL: Synthesis of tetrasubstituted ozonides by the griesbaum coozonolysis reaction: diastereoselectivity and functional group transformations by post-ozonolysis reactions. J. Org. Chem. (2004) 69(19):6470-6473.
81. O'NEILL PM: Medicinal chemistry - a worthy adversary for malaria. Nature (2004) 430(7002):838-839.
82. PETERS W: The problem of drug-resistance in malaria. Parasitology (1985) 90:705-715.
83. BASCO LK, SAME-EKOBO A, NGANE VF et al.: Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. Bull. World Health Org. (2002) 80(7):538-545.
84. BLOLAND PB, ETTLING M, MEEK S: Combination therapy for malaria in Africa: hype of hope? Bull. World Health Org. (2000) 78(12):1378-1388.
85. VAN VUGT M, LOOAREESUWAN S, WILAIRATANA P et al.: Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. (2000) 94(5):545-548.
86. WHITE N: Antimalarial drug resistance and combination chemotherapy. Philosophical Trans. R. Soc. London Series B-Biol. Sci. (1999) 354(1384):739-749.
87. WHITE NJ: Preventing antimalarial drug resistance through combinations. Drug Resist. Update (1998) 1(1):3-9.
88. DEPOORTERE E, GUTHMANN JP, PRESSE J et al.: Efficacy and effectiveness of the combination of sulfadoxine/pyrimethamine and a 3-day course of artesunate for the treatment of uncomplicated falciparum malaria in a refugee settlement in Zambia. Trop. Med. Int.l Health (2005) 10(2):139-145.
89. MARQUINO W, HUILCA M, CALAMPA C et al.: Efficacy of mefloquine and a mefloquine-artesunate combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria in the Amazon Basin of Peru. Am. J. Trop. Med. Hyg. (2003) 68(5):608-612.
90. DAVIS TME, HUNG TY, SIM IK, KARUNAJEEWA HA, ILETT KF: Piperaquine - a resurgent antimalarial drug. Drugs (2005) 65(1):75-87.
91. DENIS MB, DAVIS TME, HEWITT S et al.: Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin. Infect. Dis. (2002) 35(12):1469-1476.
92. DECHY-CABARET O, BENOIT-VICAL F, ROBERT A, MEUNIER B: Preparation and antimalarial activities of 'trioxaquines', new modular molecules with a trioxane skeleton linked to a 4-aminoquinoline. Chembiochem (2000) 1(4):281-283.
93. BASCO LK, DECHY-CABARET O, NDOUNGA M et al.: In vitro activities of DU-1102, a new trioxaquine derivative, against Plasmodium falciparum isolates. Antimicrob. Agents Chemother. (2001) 45(6):1886-1888.
94. MEUNIER B: From studies on artemisinin derivatives to trioxaquines. J. Porphyrins Phthalocyanines (2002) 6(4):271-273.
95. DECHY-CABARET O, ROBERT A, MEUNIER B: Synthesis and stereochemical study of a trioxaquine prepared from cis-bicyclo 3.3.0 ocune-3,7-dione. Comptes Rendus Chimie (2002) 5(4):297-302.
96. SINGH C, MALIK H, PURI SK: Synthesis and antimalarial activity of a new series of trioxaquines. Bioorg. Med. Chem. (2004) 12(5):1177-1182.
97. ARAUJO NC, WARD SA, DAVIES J, BRAY PG, O'NEILL PM: Semi-synthetic and synthetic 1,2,4-trioxaquines and 1,2,4-trioxoquines: synthesis and preliminary SAR. J. Med. Chem. (2005) (Manuscript in preparation).
98. GRELLEPOIS F, GRELLIER P, BONNET-DELPON D, BEGUE JP: Design, synthesis and antimalarial activity of trifluoromethylartemisinin-mefloquine dual molecules. Chembiochem (2005) 6(4):648-652.
99. O'NEILL PM, STOCKS PA, PUGH MD et al.: Design and synthesis of endoperoxide antimalarial prodrug models. Angew. Chem. Int. Ed. (2004) 43(32):4193-4197.
100. BORSTNIK K, PAIK IH, SHAPIRO TA, POSNER GH: Antimalarial chemotherapeutic peroxides: artemisinin, yingzhaosu A and related compounds. Int. J. Parasitol. (2002) 32(13):1661-1667.
101. MAGGS JL, BISHOP LPD, BATTY KT et al.: Hepatocellular bioactivation and cytotoxicity of the synthetic endoperoxide antimalarial arteflene. Chem. Biol. Interact. (2004) 147(2):173-184.